News and Press Releases
Thermo Fisher Scientific’s Clinical Research Business Recognized by ISG for Digital Services Leadership
The PPD clinical research business has been named a leader in digital solutions and services by ISG for four consecutive years 14 August 2024 -- North Carolina, US -- The...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: August 15, 2024
Basecamp Research and Cameroon announce pioneering access and benefit-sharing partnership, spotlighting new economic model before COP 16
Access and benefit-sharing agreement showcases Basecamp Research’s unique economic model: Training, data-sharing, molecular lab and in-country research funding for Cameroon scientists Royalties for when digital sequence information collected is used...
Category: Biotechnology
Posted: August 14, 2024
New Kite Clinical Research and Real-World Evidence for Yescarta (Axicabtagene ciloleucel) Demonstrate Benefit From Earlier Lines of Treatment
Analysis shows manufacturing of axicabtagene ciloleucel in second-line treatment of relapsed/refractory large B-cell lymphoma can help reduce time from leukaepheresis to infusion vs third-line plus treatment Data builds on previous...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 14, 2024
Kite Receives European Medicines Agency Approval of Safety Monitoring Variation for CAR T-Cell Therapy Portfolio
In-hospital patient monitoring for adverse events reduced from ten to seven days following CAR T-cell therapy infusion 6 June 2024 -- Stockley Park, UK -- Kite, a Gilead Company, today...
Category: Biotechnology, Other, Pharmaceutical
Posted: June 6, 2024
Kite’s TECARTUS (Brexucabtagene Autoelucel) Demonstrates Sustained Overall Survival in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia
After more than four years of follow-up in the pivotal ZUMA-3 study, median overall survival was 26 months and four-year overall survival rate was 40% at 48 months Survival benefit...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 3, 2024
Encouraging New Data Presented on Kite’s YESCARTA (Axicabtagene Ciloleucel) for Relapsed/Refractory Central Nervous System Lymphoma
At median follow-up of 24.2 months, no apparent additional risks of adverse events related to axicabtagene ciloleucel were seen Findings also suggest efficacy trend with median progression-free survival and durability...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 3, 2024
KITE Shares New Data at EHA 2024 Which Demonstrates Positive Patient Outcomes and Advances in Delivery of CAR T-Cell Therapy
Analysis comparing real-world and clinical trial data shows Yescarta (Axicabtagene Ciloleucel) has higher manufacturing success rates and improved T-cell performance, respectively, in second-line vs third-line+ treatment of large B-cell lymphoma...
Category: Clinical Trials, Pharmaceutical
Posted: May 14, 2024
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
Non-Small Cell Lung Cancer (NSCLC) Development Program Data to be Presented, Including the phase 3 EVOKE-01 Study Updated Results from phase 2 EDGE-Gastric Study of Fc-Silent Anti-TIGIT Domvanalimab Plus Anti-PD-1...
Category: Clinical Trials, Drug Discovery
Posted: May 7, 2024
Gilead Sciences Appoints Peter Wickersham to Vice-President and General Manager in the UK and Ireland
7 May 2024 -- London, UK -- Gilead Sciences announced today the appointment of Peter Wickersham as vice-president and general manager for the UK and Ireland. In his new role,...
Category: Drug Discovery, Pharmaceutical
Posted: May 7, 2024
Kite to Present Comparison of Outcomes of Tecartus (brexucabtagene autoleucel) from the Pivotal ZUMA-2 Trial Versus the EBMT Registry of alloSCT Patients in Mantle Cell Lymphoma (MCL) at 50th EBMT 2024
Additional analysis demonstrates cost-effectiveness of axicabtagene ciloleucel versus standard of care as second-line therapy In patients With large B-cell lymphoma In Italy 9 April 2024 -- Stockley Park, UK --...
Category: Biotechnology, Clinical Trials
Posted: April 12, 2024
Veklury (remdesivir) recommended by NICE for treatment of COVID-19 in vulnerable adults and children
Remdesivir is the first antiviral treatment recommended by NICE to treat eligible children, including those with a high risk of serious illness from COVID-19 This decision secures long-term access to...
Category: Pharmaceutical
Posted: April 9, 2024
Gilead extends partnership with NHS England to eliminate hepatitis C by 2025
Since the commencement of the Strategic Procurement agreement in 2019, Gilead has worked in partnership with NHS England, non-profit organisations, and industry to help treat and cure over 84,000 people...
Category: Other, Pharmaceutical
Posted: April 8, 2024
Kite Presents New Data for Yescarta (axicabtagene ciloleucel) CAR T-cell Therapy Highlighting Manufacturing Excellence and Cost-Effectiveness in the US
Data Highlights Industry-leading Manufacturing Success Rates for US Axicabtagene Ciloleucel Patients from Launch to Present Data Also Supports Cost-effectiveness of Axicabtagene Ciloleucel Versus Bispecific Antibodies 16 February 2024 – Stockley...
Category: BioManufacturing
Posted: February 21, 2024
Gilead Sciences Strengthens Commitment to Inflammatory Disease with New Research Centre
14 February 2024 -- Oxford, UK -- On 14 February, Gilead Sciences held a ribbon-cutting event to celebrate the opening of its new research site at the Business Park in...
Category: BioManufacturing
Posted: February 14, 2024
New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s TECARTUS (brexucabtagene autoleucel) in patients with aggressive blood cancers
At Almost Four Years of Follow-up in the Pivotal ZUMA-2 Study, Median Overall Survival was 46.4 Months, Supporting Long-term Response in Adult Patients with Relapsed/Refractory(R/R) Mantle Cell Lymphoma (MCL) Real-world...
Category: Clinical Trials
Posted: December 12, 2023
